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Abstract: 3-Nitro-1H-1,2,4-triazole-based amides with a linear, rigid core and 3-nitrotriazole-
based fluconazole analogs were synthesized as dual functioning antitrypanosomal agents. Such 
compounds are excellent substrates for type I nitroreductase (NTR) located in the mitochondrion 
of trypanosomatids and, at the same time, act as inhibitors of the sterol 14-demethylase (T. 
cruzi CYP51) enzyme. Because combination treatments against parasites are often superior to 
monotherapy, we believe that this emerging class of bifunctional compounds may introduce a 
new generation of antitrypanosomal drugs. In the present work, the synthesis and in vitro and in 
vivo evaluation of such compounds is discussed. 
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 INTRODUCTION 
About one sixth of the world’s population, most living in developing countries, suffer from a 
series of infections collective known as neglected tropical diseases (NTDs).
1
 In addition to 
killing more than 500,000 people each year, these illnesses impair physical and cognitive 
development of children, make it difficult to farm or earn a living, and limit productivity in the 
workplace. Two NTDs are American trypanosomiasis (also known as Chagas disease), which is 
causes by the protozoan parasite Trypanosoma cruzi and is endemic in 21 countries across Latin 
America, and human African trypanosomiasis (HAT) (also known as African sleeping sickness), 
which is prevalent across sub-Saharan Africa and caused by T. brucei rhodesiense and T. brucei 
gambiense  Although the number of incidences of both infections has significantly declined in 
the past 20 years due to implementation of vector control initiatives, the diseases still remain a 
major global health issue, especially since the number of cases in non-endemic sites (United 
States, Australia, Europe and Japan) is rising, primarily due to international population migration 
and transfusion of contaminated blood.
2-4
  
The therapeutic options for Chagas are currently limited to two drugs, both nitroheterocyclic 
compounds, nifurtimox (Nfx; Lampit®) and benznidazole (Bnz; Rochagan®), while the success 
of treatment depends on the phase of the disease. Thus, cure rates of 65-80% can be achieved in 
the acute phase, whereas only 15-30% cure rates have been reported among adults in the chronic 
stage.
5, 6
 Besides the low efficacy in patients with chronic disease, safety and tolerability issues 
are also major drawbacks for these drugs. Therefore, the development of new, safer and more 
effective therapeutic treatments remains a key challenge for Chagas disease control. 
Currently, inhibitors of the fungal sterol 14-demethylase enzyme (CYP51) represent a new 
form of treatment against Chagas disease and demonstrated promising efficacy in preclinical 
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studies.
7, 8
 Additional pathogen-specific drug discovery efforts have resulted in inhibitors for the 
orthologous enzyme T. cruzi CYP51 (TcCYP51).
9-12
 One such compound, VNI, showed 
parasitological cures in both the acute and chronic in vivo Chagas model.
11
 However, the 
antifungal agent posaconazole revealed 80% treatment failure in clinical trials in human 
patients with chronic Chagas disease while Bnz was proven more efficacious.
13
  In addition, in 
newly designed in vitro assays, nitroheterocyclic compounds were more efficacious trypanocidal 
agents than four different CYP51 inhibitors, including antifungal drugs posaconazole and 
ravuconazole and two pyridine-based compounds,
14
 suggesting that inhibitors of sterol 
biosynthesis may not be as efficient as single chemotherapeutic agents against Chagas disease as 
they are against fungal infections. Interestingly, a recent study with Bnz and posaconazole 
administered concomitantly or in sequence suggested a positive interaction between the two 
drugs, at least in an acute murine infection model.
15
 
We have recently demonstrated that another class of nitroheterocyclic compounds, 3-nitro-
1H-1,2,4-triazoles, are very potent antichagasic agents both in vitro and in vivo, whereas several 
analogs showed very good in vitro efficacy against T. brucei rhodesiense as well.
16-19
 These 
studies clearly demonstrated that 3-nitrotriazole-based compounds are significantly more potent 
and less toxic than their 2-nitroimidazole-based counterparts,
19, 20
 
 
with part of the trypanocidal 
activity being dependent on the parasite’s expression of an oxygen-insensitive type I 
nitroreductase (NTR), an enzyme absent from most other eukaryotes.
16, 17, 19
 This same enzyme, 
via a series of 2 electron reduction reactions which lead to the production of toxic metabolites, is 
responsible for the trypanocidal activity of Nfx, Bnz and other nitroheterocyclic  prodrugs in 
general.
21-24
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In this work we examined the possibility of synthesizing dual-functioning 3-nitrotriazole-
based compounds; such compounds could potentially act as prodrugs via their reducible nitro-
group and, at the same time, be inhibitors of CYP51 enzyme via their triazole-based scaffold.
25
 
The synthesis of bifunctional agents has the advantage of combining the beneficial effects of 
nitroheterocyclics with the beneficial effects of ergosterol biosynthesis inhibitors in one 
molecule. To accomplish this task, we synthesized and evaluated in vitro and in vivo linear, rigid 
3-nitrotriazole-based amides and 3-nitrotriazole-based carbinols (analogs of fluconazole), as 
potential antitrypanosomal/antichagasic agents, NTR substrates and TcCYP51 inhibitors.  
 
 RESULTS AND DISCUSSION  
Chemistry  
The structures of synthesized compounds are shown in Table 1. Their synthesis is 
straightforward and based on well-established chemistry outlined in Scheme 1. Thus, amides 2-9 
were obtained by nucleophilic substitution of chloroacetamides 1a-g with the potassium salt of 
3-nitrotriazole or 2-nitroimidazole under refluxing conditions. Similarly, nitro(triazole/ 
imidazole)-ketones 10-13 were synthesized by nucleophilic substitution of -bromoketones. 
Carbinols 14-19 were obtained in one step by using a modified Corey-Chaykovsky reaction;
26
 in 
this one-pot reaction, trimethylsulfoxonium iodide was used in a 2-propanol : aqueous KOH 
(1:1) solution and the appropriate ketone was added to form in situ an oxirane; then 3-
nitrotriazole was added followed by 1-h refluxing. Although the yields by using this method 
were low, the method is attractive due to its simplicity and short reaction time. The obtained 
carbinols 14-19 were used as racemic mixtures. When 2-nitroimidazole was used in the modified 
Corey-Chaykovsky reaction, the bicyclic compound 20 was formed as the final product, 
6 
 
presumably via an intramolecular aromatic nucleophilic substitution of the nitro-group by the 
hydroxyl-group. The sulfonamide 21 was formed by nucleophilic attack of the sodium salt of 3-
nitrotriazole with the appropriate aziridine-sulfonamide (Scheme 1). 
Biological Evaluation. 
Anti-parasitic activity. Compounds were tested for antitrypanosomal activity against T. cruzi 
amastigotes and bloodstream form (BSF) of T. b. rhodesiense.  Dose response curves were 
constructed from which the concentration of compound that inhibits parasite growth by 50 % 
(IC50) was calculated for each parasite (Table 1). In addition, compounds were tested for toxicity 
in L6 rat skeletal myoblasts, the host cells for T. cruzi amastigotes, in order to calculate a 
selectivity index for each parasite (SI = IC50L6/IC50parasite) (Table 1). The TDR (Special 
Programme for Research and Training in Tropical Diseases, World Health Organization) criteria 
for activity were adapted to interpret the data.
27
 Thus, for T. cruzi amastigotes, an IC50 of <4.0 
µM, between 4.0-60 µM or >60 µM, designates ‘active’, ‘moderately active’ or ‘inactive’ 
compounds, respectively, whereas for BSF T. b. rhodesiense, IC50 values of <0.5 µM, between 
0.5-6.0 µM or > 6.0 µM identify ‘active’, ‘moderately active’ or ‘inactive’ compounds, 
respectively. In addition, SI values should ideally be ≥50 and ≥100 for T. cruzi and T. b. 
rhodesiense, respectively.
27
  
All the 3-nitrotriazole-based rigid amides (2, 3, 5, 6, 8, 9) except 4, and all the 3-
nitrotriazole-based carbinols (14, 17-19), as well as the fluconazole-like 3-nitrotriazole-based 
sulfonamide 21, were active antichagasic agents with acceptable selectivity indices (Table 1). 
Only 3 compounds (two 3-nitrotriazole-based amides and one 3-nitrotriazole-based carbinol) 
were active (2) or moderately active (5, 14) anti-HAT agents with acceptable SI values. In 
addition, ketone 11, the precursor of carbinol 19 showed a moderate anti-HAT activity with 
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acceptable selectivity. As observed before, compound 7, the 2-nitroimidazole-based analog of 6, 
was borderline active against T. cruzi amastigotes but with an unacceptable SI value (Table 1). 
 
Analysis of antichagasic activity. Linear, rigid amides 2-9: Although a detailed SARs 
evaluation cannot be conducted due to the limited number of compounds studied, we made the 
following observations: A chloro-substituent in the para position of a diphenyl-core in the rigid 
amide 5 increased the efficacy against T. cruzi by a factor of 3 compared to the cyano-substituted 
analog 2. Although 5 was slightly more toxic to L6 cells than compound 2, its SI for T. cruzi was 
also increased about 2-fold compared to 2 due to its better anti-chagasic efficacy; this cannot be 
attributed to lipophilicity since both compounds share similar clogP values, but perhaps to its 
lower PSA value (Table 1).  Chloro-substitution in the phenylthiazole-core of 3 was also 
beneficial for  its antichagasic activity and selectivity compared to the difluoro-substitution in the 
analog 6. However, in this case, increased antichagasic efficacy may be related to the increased 
lipophilicity of 3 compared to 6. Reversing the order between the thiazole and phenyl rings in 
amide 8 slightly decreased antichagasic activity compared to 6 and once again, this reduction 
may be related to slightly lower lipohilicity compared to 6. Furthermore, this reversal lead to a 
slightly more toxic compound (compare 8 to 3 and 6). Replacing the terminal phenyl ring in the 
biphenyl core of 2 or 5 with a piperidinic group in 9, resulted in reduced efficacy against T. 
cruzi, which seems to be attributed to a decreased clogP value (Table 1). Compound 4 with a 
thiodiazole ring in the rigid core failed to show either good antichagasic activity or acceptable 
selectivity. However, compound 4 has significant solubility problems and may have not been 
evaluated properly. Although compound 7, the 2-nitroimidazole analog of 6, showed borderline  
antichagasic activity according to the TDR criteria, it was the most toxic rigid amide in L6 cells 
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and failed to show an acceptable SI for T. cruzi. Compound 7 was about 8.7-fold less active 
against T. cruzi compared to its 3-nitrotriazole-analog 6, even though the latter was 1.5 times less 
lipophilic, suggesting that the reason for the reduced antichagasic activity of 7 was related to the 
2-nitroimidazole ring. All 3-nitrotriazole-based rigid amides, except 4, were more potent 
antichagasic agents than Bnz, with compound 5 being 45-fold more potent than Bnz (Table 1). 
Carbinols and  their precursors. With regard to the carbinols in Table 1, which were racemic 
mixtures, we observe the following: Lipophilicity and the presence of the nitro-group in the 
triazole-ring played a significant role in the antichagasic activity. Thus, the 3-nitrotriazole-based 
carbinol 14, with a terminal imidazole ring in the core, was significantly less lipophilic than 
carbinol 17, with a terminal phenyl ring in the core, and 32-fold less potent against T. cruzi 
amastigotes than 17 (Table 1). On the other hand, carbinol 15, the analog of 14 without the 3-
nitro group in the triazole ring, had a negative clogP value and was inactive against T. cruzi. 
Interestingly, carbinol 16, the analog of 17 without the 3-nitro group in the triazole ring, was still 
active against T. cruzi, most likely because of its relatively high lipophilicity. However, the lack 
of the nitro-group resulted in a 7-fold reduction in antichagasic potency compared to 17. 
Carbinol 18 is the mono-nitrotriazole analog of fluconazole. This compound was 36-fold less 
potent than its more lipophilic analog 19, which has an additional phenyl ring in the side chain. 
However, compound 18 was 8.5-fold more potent than fluconazole, which is less lipophilic and 
lacks the nitro-group (Table 1).   Carbinol 19 was the most potent antichagasic compound tested 
and demonstrated the highest SI value. In addition, 19 was about 68-fold more potent than Bnz 
(Table 1). The bicyclic compound 20 was formed in situ from the corresponding 2-
nitroimidazole analog of fluconazole presumably by intramolecular nucleophilic aromatic 
substitution of the nitro-group by the hydroxyl group. This compound, although slightly more 
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lipophilic than 18, was about 5-fold less potent against T. cruzi, presumably because it lacks the 
nitro group.  In addition, compound 20 was moderately active and marginally selective (SI > 
49.4) for T. cruzi parasite. In compound 21 we replaced the hydroxyl-group with a tosylamino-
group. Compound 21 was selectively active against T. cruzi, but its potency was about 3-fold less 
compared to carbinol 17 with a similar lipophilicity. An increased PSA value compared to 17 
may have played a role for this reduction in this case. 
 Some ketones, precursors of the carbinols in Table 1, were also evaluated for antichagasic 
activity. Interestingly, the 3-nitrotriazole-based ketones 10 and 11, precursors of carbinols 18 and 
19, respectively, were found to be selectively active against T. cruzi (Table 1). The pattern of 
lipophilicity and the presence of the nitro-group in the triazole ring were consistent with our 
predictions for efficacy. Thus, the more lipophilic 11 was more potent than 10, whereas ketone 
12, the analog of 11 without the nitro-group, was only moderately active against T. cruzi and did 
not fulfill the TDR selectivity criteria. Once again, the 2-nitroimidazole analog of 11, ketone 13, 
was only moderately active against T. cruzi parasites, but also the most toxic compound to the 
host cells. From this evaluation, it appears that 3-nitrotriazole-based ketones represent another 
class of antichagasic agents. Finally, compound 22, the precursor of carbinols 14 and 15, was 
inactive against T. cruzi (Table 1). 
Analysis of anti-HAT activity. Linear, rigid amides 2-9: With regard to the anti-HAT 
activity of amides 2-9, biphenyl amides 2 and 5 (which were active and moderately active, 
respectively) were more potent against T. b. rhodesiense than phenylthiazole-amides 3, 6, 7 and 
8. In fact, none of the latter demonstrated an acceptable selective anti-HAT activity (Table 1). 
The phenyl-thiodiazoleamide 4 did not show any anti-HAT activity, in part due to solubility 
issues as mentioned earlier, whereas the piperidinophenylamide 9 was inactive, perhaps because 
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of planarity issues in the side chain. Interestingly, the 2-nitroimidazole-based phenylthiazole-
amide 7 demonstrated a lower IC50 value against T. b. rhodesiense than its 3-nitrotriazole-based 
analog 6, possibly due to the higher lipophilicity of the first. Nonetheless, both were inactive 
against this parasite.  
Carbinols and their precursors. Only carbinol 14 was moderately active with acceptable 
selectivity against T. b. rhodesiense. Carbinol 17 with increased lipophilicity was more active 
than 14 but not selective enough for this parasite. Similarly, carbinol 19 was more active than the 
less lipophilic analog 18, but also lacked an acceptable selectivity for T. b. rhodesiense. Linear, 
rigid carbinols lacking the nitro-group (15, 16) were inactive against T. b. rhodesiense. 
Interestingly, the precursor of carbinol 19, the lipophilic enough 3-nitrotriazole-based ketone 11, 
was moderately active and had an acceptable selectivity for T. b. rhodesiense. 
Involvement of type I Nitroreductase. Representative 3-nitrotriazole-based linear rigid 
amides and carbinols, with IC50 values against T. cruzi ranging from 33 nM to 3.29 μM, were 
evaluated as substrates of recombinant TbNTR and TcNTR enzymes (Table 2). Enzyme specific 
activity was measured as oxidized NADH per min per mg of protein. All tested nitrotriazoles 
were excellent substrates of Tb and TcNTR enzymes. Thus, tested nitrotriazoles were 
metabolized by Tb and TcNTR at rates approximately 2-fold higher than Bnz, whereas TbNTR 
can metabolize nitrotriazoles (and Bnz) at rates 2 to 3-fold greater than those of TcNTR. In 
addition, blood stream form T. b. brucei parasites overexpressing TbNTR were 2 to 3-fold more 
susceptible to compound 2 compared to parasites not induced to express elevated levels of 
TbNTR (IC50: 0.36  0.01 vs 0.84  0.16). However, no correlation existed between parasitic 
IC50 values (Table 1) and activation rate by TcNTR or TbNTR, suggesting that antiparasitic 
activity was not exclusively dependent on NTR-induced activation.  
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TcCYP51 inhibition. Azole-based scaffolds are effective inhibitors of the T. cruzi enzyme 
sterol 14α-demethylase (TcCYP51).25 By using eburicol as substrate, TcCYP51 is a central 
enzyme in parasitic sterol biosynthesis, an essential pathway in all life stages of T. cruzi for the 
formation of ergosterol and related structures from lanosterol.
28, 29
 Being azoles, our compounds 
could be potential inhibitors of TcCYP51. Moreover, reduction of the nitro group by P450 
reductase (which normally reduces the Fe
3+
 to Fe
2+
 in the heme cofactor of CYP51) could 
potentially cause irreversible binding to the protein. Benznidazole was found to be an irreversible 
inhibitor of TcCYP51, although with weak affinity for the enzyme.
30
 Binding of a hererocyclic 
compound to CYP51 can be quantified spectroscopically by measuring a dose-response type 2 
shift that occurs upon coordination of a Lewis-base atom of the ligand to the heme iron of the 
enzyme.
9
 The first 3-nitrotriazole-based compound we tested as a potential TcCYP51 ligand was 
chlorothiophene-2-sulfonamide 23, with a flexible core (Table 1). The biological properties of 23 
have been described before
17
 and are included in Table 1 for reference. This compound displayed 
a week affinity toward TcCYP51, providing a high Kd value of 65.2  5.3 (Table 3). Therefore, 
we assumed that compounds with a more rigid core could better fit in the active site of the 
enzyme and thus act as stronger inhibitors. Indeed, compound 2 with a linear rigid core inhibited 
the enzyme with an initial I/E2 ratio (molar ratio of inhibitor/enzyme which causes a 2-fold 
decrease in enzyme activity) of 4 in a 5 min reaction. However, this ratio was increased to 36 in 
the 1 h reaction, indicating that inhibition by 2 was reversible. The 3-nitro-triazole-fluconazole 
analog 18 binds to TcCYP51 and induces the same typical type 2 spectral response as 
fluconazole (Fig. 1), indicating at least initial coordination of the triazole N4 to the P450 heme 
iron.
9
 However, 18 was a weaker binder than fluconazole (Kd 0.606 versus 0.230 μM) (Table 3). 
To the contrary, carbinol 19, an analog of fluconazole with an elongated rigid side chain, elicited 
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the spectral response in   TcCYP51 with an apparent Kd 10-fold stronger than fluconazole. In the 
reconstituted CYP51 reaction, 19 produced  I/E2 ratios of <1 and 3, in 5 min and 1 h reactions, 
respectively (Table 3 and Fig. 2). Furthermore, for carbinol 19 at high I/E ratios (≥ 20), the 
inhibition seems to be irreversible, although further experiments are needed for verification (Fig. 
2). Correlation exists between in vitro antichagasic potency and inhibition of TcCYP51 for the 
nitro-compounds 2, 19 and 23. However, compound 18 was more potent in killing T. cruzi 
amastigotes than fluconazole (Tables 1), although the latter was a stronger TcCYP51 inhibitor 
(Table 3). This might be related to the nitro-group of 18, making this compound bifunctional. 
Crystallography studies could shed more light on the orientation of these bifunctional agents in 
the TcCYP51 active site. 
In vivo antichagasic activity. Compounds 2, 5, 18 and 19 were evaluated for in vivo anti-
chagasic activity by using an acute T. cruzi infected murine model as described before.
19
 Bnz 
was used in parallel as a positive control. Infected mice (5 mice/group) were treated i.p. for up to 
10 consecutive days with each compound, at 15 mg/kg/day, except for compound 5 which was 
administered at 13 mg/kg/day. The Parasite Index (PI), which is an indicator for parasite 
clearance, was calculated after 5 and 10 days of treatment.
19
 The data from these studies are 
summarized in Fig. 3. All tested compounds reduced the PI to < 4% after 10-day treatment with 
statistical significance compared to the 10-day untreated control. The linear rigid amides 2 and 5 
were able to reduce parasites to undetectable levels even after 5 days of treatment. However, 
only compound 5 yielded a statistically significant different PI value compared to untreated 
control after 5 days of treatment (P<0.0001), whereas for Bnz and compound 2 (treated in the 
same experiment) the corresponding P value was 0.080 and 0.0819, respectively.  Carbinols 18 
and 19 provided a PI value of 24.9 and 42.04, respectively, after 5-day administration but 
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without statistical significance compared to the untreated control (P = 0.1680 and 0.2706, 
respectively). Bnz in this latter experiment provided a PI value of 13.38 after 5-day treatment, 
also not statistically different from the untreated control (P = 0.2706). None of the tested 
compounds was toxic to mice at the given doses and administration shedule.  
In vitro ADME studies. To understand better the in vivo activity of compounds 2 and 19 and 
explain the discrepancy between in vitro and in vivo potency, we performed some in vitro 
ADME studies (Table 4). Compound 2 represents the linear rigid amides and 19 the carbinols. 
Both compounds demonstrate high Caco 2 permeability
31
 and similar metabolic stability in the 
presence of mourine or human microsomes. Both compounds were quite stable, explaining their 
good in vivo activity after 10-day dosing. The fact that compound 19 was acting slower than 2 
may be related to its stronger binding to TcCYP51, a membrane protein, whereas type I NTR is 
mitochondrial based. Thus, if compound metabolites formed through NTR-activation are the 
most toxic chemical species for T. cruzi, compound 2 would be expected to act faster than 19. 
Obviously, additional pharmacokinetic parameters (such as volume distribution and protein 
binding) which can affect the in vivo behavior of these compounds cannot be excluded. 
It is concluded from the above data that 3-nitrotriazole-based linear rigid amides and 
carbinols are potent antichagasic agents via their dual functioning properties as substrates for 
trypanosomal type I NTR and as inhibitors of CYP51. In addition, these compounds demonstrate 
excellent Caco 2 permeability and metabolic stability in the presence of human or murine 
microsomes. Carbinols were slower in clearing the parasites in vivo compared to the linear rigid 
amides, however, both type of compounds were able to clear T. cruzi after 10-day treatment. 
This is apparent in the images shown in Fig. 4. Future experiments in a chronic murine model are 
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necessary to determine the validity of these bifunctional compounds for the treatment of Chagas 
disease. 
 EXPERIMENTAL 
Chemistry. General: All starting materials and solvents were purchased from Sigma-Aldrich 
(Milwaukee, WI), were of research-grade quality and used without further purification. Solvents 
used were anhydrous and the reactions were carried out under a nitrogen atmosphere and 
exclusion of moisture.  Melting points were determined by using a Mel-Temp II Laboratory 
Devices apparatus (Holliston, MA) and are uncorrected. Proton NMR spectra were obtained on a 
Varian Inova-500 or an Agilent Hg-400 spectrometer at 500 or 400 MHz, respectively, and were 
referenced to Me4Si or to the corresponding solvent if the solvent was not CDCl3. High-
resolution electrospray ionization (HRESIMS) mass spectra were obtained on a Agilent 6210 
LC-TOF mass spectrometer at 11000 resolution.  Thin-layer chromatography was carried out on 
aluminum oxide N/UV254 or polygram silica gel G/UV254 coated plates (0.2 mm, Analtech, 
Newark, DE). Chromatography was carried out on preparative TLC alumina GF (1000 microns) 
or silica gel GF (1500 microns) plates (Analtech). All compounds were purified by preparative 
TLC chromatography on silica gel or alumina plates and also checked by HPLC (≥ 95% purity).   
 Synthesis of chlorides 1a-g: Some of the chlorides 1a-g are known in the literature and others 
are unknown or known through libraries but without any reference. The synthesis and 
spectroscopic data of 1a-g are provided in the supporting material. 
General Synthetic Procedure of amides 2-9: The potassium salt of 3-nitro-1,2,4-triazole or 2-
nitroimidazole (1 eq) was formed in CH3CN (6-10 mL), by refluxing with KOH (1.2 eq) for 30 
min. To this suspension 1a-g (1.1 eq) was added and the reaction mixture was refluxed under a 
nitrogen atmosphere for 9 h. In certain cases, 1a-g was added in CH3CN solution. The reaction 
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mixture was checked by TLC for completion of the reaction and the solvent was evaporated. The 
residue was dissolved in ethyl acetate and the inorganic salts were filtered away. Upon 
preparative TLC (silica gel or alumina, depending on the mobility of the major band; ethyl 
acetate-petroleum ether), the desired product was obtained usually as a powder. Purity was 
checked also by HPLC and it was > 95%.   
N-[4-(4-cyanophenyl)phenyl]-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (2): 
White microcrystallic powder (80%): mp 235 
o
C (dec); 
1
H NMR (500 MHz, (CD3)2CO) δ: 9.84 
(br s, 1H), 8.76 (s, 1H), 7.90-7,75 (m, 8H), 5.46 (s, 2H). HRESIMS calcd for C17H13N6O3 and 
C17H12N6NaO3 m/z [M+H]
+
 and [M+Na]
+  
349.1044 and 371.0863, found 349.1056 and 
371.0873.  
N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (3): 
White powder (64%): mp > 235 
o
C; 1H NMR (500 MHz, (CD3)2CO) δ: 8.82 (s, 1H), 7.95 (d, J=8.5 
Hz, 2H), 7.64 (s, 1H), 7.46 (d, J=8.5 Hz, 2H), 5.70 (s, 2H). HRESIMS calcd for C13H10ClN6O3S and 
C13H9ClN6NaO3S m/z [M+H]
+
 and [M+Na]
+  
365.0218, 367.0191 and 387.0038, 389.0011, found 
365.0231, 367.0200 and 387.0038, 389.0012. 
N-[5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl]-2-(3-nitro-1H-1,2,4-triazol-1-yl) acetamide (4): 
White powder (63%): mp > 235 
o
C; 
1
H NMR (500 MHz, DMSO-6d) δ: 8.93 (s, 1H), 7.96 (d, 
J=8.5 Hz, 2H), 7.60 (d, J=8.5 Hz, 2H), 5.57 (s, 2H). HRESIMS calcd for C14H11ClN4O4S m/z [M+H]
+
 
366.0184, 368.0148, found 366.0178, 368.0158. 
N-(4'-chloro-[1,1'-biphenyl]-4-yl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (5): Off white 
powder (77%): mp > 245 
o
C; 
1
H NMR (500 MHz, CD3OD + a drop of DMSO-6d) δ: 8.73 (s, 
1H), 7.69 (d, J=9.0 Hz, 2H), 7.61 (dd, J=9.0, 4.0 Hz, 4H), 7.43 (d, J=8.0 Hz, 2H), 5.32 (s, 2H). 
HRESIMS calcd for C16H11ClN5O3 m/z [M-H]
-
 356.05556, found 356.0563. 
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N-(4-(3,4-difluorophenyl)thiazol-2-yl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (6): White 
powder (60%): mp 169-171 
o
C; 1H NMR (500 MHz, (CD3)2CO) δ: 11.71 (br s, 1H), 8.80 (s, 1H), 
7.83 (ddd, J=14, 7.5, 2 Hz, 1H), 7.76 (m, 1H), 7.64 (s, 1H), 7.37 (dd, J= 19, 8.5 Hz, 1H), 5.69 (s, 2H). 
HRESIMS calcd for C13H9F2N6O3S m/z [M+H]
+
 367.0419, found 367.0426. 
N-(4-(3,4-difluorophenyl)thiazol-2-yl)-2-(2-nitro-1H-imidazol-1-yl)acetamide (7): Off white 
powder (55%): mp 180-183 
o
C (dec); 1H NMR (500 MHz, (CD3)2CO) δ: 11.70 (br s, 1H), 7.82 (ddd, 
J=12, 7.5, 2.5 Hz, 1H), 7.77 (m, 1H), 7.63 (s, 1H),  7.61 (s, 1H), 7.36 (ddd, J= 16.5, 10.5, 8.5 Hz, 1H), 
7.22 (s, 1H), 5.70 (s, 2H). HRESIMS calcd for C14H10F2N5O3S and  C14H9F2N5NaO3S  m/z [M+H]
+
 and 
[M+Na]
+
 366.0467 and 388.0286 found 366.0466 and 388.0281. 
 N-(3-(2-methylthiazol-4-yl)phenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (8): White, 
sticky solid (73%): mp  114-115 
o
C (dec); 
1
H NMR (400 MHz, CDCl3 + 2 drops DMSO-6d) δ: 
10.39 (s, 1H), 8.61 (s, 1H), 8.11 (s, 1H), 7.62 (d, J=7.6 Hz, 2H), 7.39 (s, 1H), 7.36 (t, J=8.0 Hz, 1H), 
5.27 (s, 2H), 2.75 (s, 3H). HRESIMS calcd for C14H13N6O3S m/z [M+H]
+
 345.0764, found 345.0776. 
2-(3-nitro-1H-1,2,4-triazol-1-yl)-N-(4-(piperidin-1-yl)phenyl)acetamide (9): Orange 
microcrystals (79%): mp 180-182 
o
C (dec); 
1
H NMR (400 MHz, CDCl3 + 1 drop DMSO-6d) δ: 
9.19 (br s, 1H), 8.44 (s, 1H), 7.37 (d, J=9.0 Hz,2H), 6.87 (d, J=9.0 Hz, 2H), 5.10 (s, 2H), 3.10 (t, J=5.5 
Hz, 4H), 1.68 (m, 4H), 1.57 (m, 2H). HRESIMS calcd for C15H19N6O3 m/z [M+H]
+
 331.1513, found 
331.1523. 
General Synthetic Procedure of ketones 10-13: As in the case of amides 2-9, the potassium salt of 3-
nitro-1,2,4-triazole or 2-nitroimidazole or  1,2,4-triazole (1 eq) was formed in CH3CN (6-10 ml), by 
refluxing with KOH (1.2 eq) for 30 min and the appropriate -bromoketone (1 eq) was added to this 
suspension. The reaction mixture was refluxed under nitrogen atmosphere for 5-6 h. The procedure for 
separation of the desired ketones 10-13 was analogous to that used for amides 2-9. 
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1-(2,4-difluorophenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)ethan-1-one (10): White crystals 
(85%): mp 102-104 
o
C; 
1
H NMR (500 MHz, CDCl3) δ: 8.30 (s, 1H), 8.09 (dd, J=9.0, 7.0 Hz, 1H), 
7.10 (td, J=9.5, 2.5 Hz, 1H), 7.02 (td, J=9.0, 2.5 Hz, 1H), 5.69 (d, J=3.0 Hz, 2H). HRESIMS calcd for 
C10H7F2N4O3 m/z [M+H]
+
 269.0481, found 269.0487. 
1-(4-phenylphenyl)-2-(1H-1,2,4-triazol-1-yl)ethan-1-one (11): White powder (95%): mp 
175-177 
o
C; 
1
H NMR [500 MHz, (CD3)2CO] δ: 8.67 (s, 1H), 8.16 (d, J=8.5, 2H), 7.84 (d, J=8.5, 
2H), 7.70 (d, J=7.5, 2H), 7.48 (t, J=7.5, 2H), 7.41 (t, J=7.5, 1H), 6.15 (s, 2H). HRESIMS calcd for 
C16H13N4O3 and C16H12N4NaO3 m/z [M+H]
+
 and [M+Na]
+
 309.0982 and 331.0802 found 309.0983 and 
331.0804. 
1-(4-phenylphenyl)-2-(1H-1,2,4-triazol-1-yl)ethan-1-one (12): White microcrystals (65%; 
higher yield based on recovered ketone): mp 159-161 
o
C; 
1
H NMR (400 MHz, CDCl3) δ: 8.28 (s, 
1H), 8.07 (d, J=8.8 Hz, 2H), 8.03 (s, 1H), 7.76 (d, J=8.8 Hz, 2H), 7.64 (d, J=6.8 Hz, 2H), 7.52-7.44 (m, 
3H), 5.71 (s, 2H). HRESIMS calcd for C16H14N3O m/z [M+H]
+
 264.1131, found 264.1154. 
2-(2-nitro-1H-imidazol-1-yl)-1-(4-phenylphenyl)ethan-1-one  (13): White powder (60 %): 
mp 163-164 
o
C; 
1
H NMR [500 MHz, (CD3)2CO] δ: 8.20 (d, J=9.0 Hz, 2H), 7.92 (d, J=9.0 Hz, 2H), 
7.78 (d, J=7.0 Hz, 2H), 7.57 (d, J=1.0 Hz, 1H), 7.53 (t, J=7.5 Hz, 2H), 7.46 (t, J=7.5 Hz, 1H), 7.23 (d, 
J=1.0 Hz, 1H), 6.26 (s, 2H). HRESIMS calcd for C17H14N3O3 m/z [M+H]
+
 308.1030, found 308.1028. 
General Synthetic Procedure of carbinols 14-19 and compound 20: The Corey-Chaykovsky reaction 
was applied for this synthesis and a one-pot reaction was adapted from an international patent
26
 because 
of its short time, albeit with low yields. Briefly, in a 2-necked 25 mL round bottom flask, KOH (2.4 eq) 
was dissolved in 3 mL distilled water and an equal volume of 2-propanol was added. 
Trimethylsulfoxonium iodide (1.2 eq) was added and stirred for 15 min under a nitrogen atmosphere. 
Then, the appropriate ketone (1 eq) was added and stirring was continued for 15 min. Finally 3-nitro-
1,2,4-triazole or 2-nitroimidazole or 1,2,4-triazole (1.2 eq) was added and the reaction mixture was 
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refluxed for 1 h. 2-Propanol was evaporated and the aqueous solution was neutralized with 1% HCl. This 
solution was then extracted with dichloromethane and the organic layer washed with NaHCO3 solution. 
The organic layer was dried over Na2SO4 and chromatographed by preparative TLC (silica gel, ethyl 
acetate plus 1% MeOH). When 2-nitroimidazole was used in the reaction mixture, a nucleophilic aromatic 
substitution of the nitro-group by the hydroxyl took place and the bicyclic-compound 20 was obtained as 
the final product.  
2-[4-(1H-imidazol-1-yl)phenyl]-1-(3-nitro-1H-1,2,4-triazol-1-yl)propan-2-ol (14): Off white 
powder (15%): mp 133-134 
o
C; 
1
H NMR [500 MHz, (CD3)2CO] δ: 8.47 (s, 1H), 8.06 (s, 1H), 7.72 
(d, J=8.5 Hz, 2H), 7.60 (d, J=8.5 Hz, 2H), 7.58 (s, 1H), 7.10 (s, 1H), 5.09 (s, 1H), 4.69 (d, J=4.5 Hz, 2H), 
1.68 (s, 3H). HRESIMS calcd for C14H15N6O3 m/z [M+H]
+
 315.1200, found 315.1207. 
2-[4-(1H-imidazol-1-yl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol (15): White  powder 
(32%): mp 138-140 
o
C; 
1
H NMR [500 MHz, (CD3)2CO] δ: 8.20 (s, 1H), 8.05 (s, 1H), 7.80 (s, 1H), 
7.66 (d, J=8.5 Hz, 2H), 7.56 (d, J=8.5 Hz, 2H), 7.10 (s, 1H), 4.89 (s, 1H), 4.54 (d, J=4.0 Hz, 2H), 1.57 (s, 
3H).HRESIMS calcd for C14H16N5O m/z [M+H]
+
 270.1349, found 270.1363. 
2-(4-phenylphenyl)-1-(1H-1,2,4-triazol-1-yl)propan-2-ol (16): White powder (37%; based on 
recovered ketone the yield was 50%): mp 118-120 
o
C; 
1
H NMR [500 MHz, (CD3)2CO] δ: 1H 
8.20 (s, 1H), 7.81 (s, 1H), 7.67-7.61 (m, 6H), 7.45 (t, J=7.5 Hz, 2H), 7.35 (t, J=7.5 Hz, 1H), 4.79 (s, 1H), 
4.43 (s, 2H), 1.55 (s, 3H). HRESIMS calcd for C17H18N3O m/z [M+H]
+
 280.1444, found 280.1453. 
1-(3-nitro-1H-1,2,4-triazol-1-yl)-2-(4-phenylphenyl)propan-2-ol (17): White powder (19%): 
mp was not determined; 
1
H NMR (500 MHz, CDCl3) δ: 8.17 (s, 1H), 7.63-7.58 (m, 4H), 7.51-7.44 
(m, 4H), 7.38 (t, J=7.0 Hz, 1H), 4.52 (d, J=3.5 Hz, 2H), 1.67 (s, 3H). HRESIMS calcd for C17H16N4NaO3 
m/z [M+Na]
+
 347.1115, found 347.1124. 
2-(2,4-difluorophenyl)-1-(3-nitro-1H-1,2,4-triazol-1-yl)-3-(1H-1,2,4-triazol-1-yl)-propan-2-
ol (18): White powder (25%): mp 154-156 
o
C; 
1
H NMR (400 MHz, CDCl3) δ: 8.32 (s, 1H), 7.94 
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(s, 1H), 7.87 (s, 1H), 7.42 (ddd, J=8.8, 6.4, 2.4 Hz, 1H), 6.88-6.79 (m, 2H), 5.66 (s, 1H), 4.99 (d, J=14.4 
Hz, 1H), 4.76 (d, J=14.4 Hz, 1H), 4.64 (d, J=14.0 Hz, 1H), 4.34 (d, J=14.0 Hz, 1H). HRESIMS calcd for 
C13H19F2N7O3 m/z [M+H]
+
 352.09697, found 352.0980. 
1-(3-nitro-1H-1,2,4-triazol-1-yl)-2-(4-phenylphenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol 
(19): White powder (33%): mp 90-93 
o
C (dec); 
1
H NMR [500 MHz, (CD3)2CO] δ: 8.46 (s, 1H), 
8.23 (s, 1H), 7.86 (s, 1H), 7.65-7.60 (m, 6H), 7.45 (t, J=8.0, 2H), 7.36 (t, J=7.5, 1H), 5.57 (s, 1H), 4.98 (d, 
J=14.0, 1H), 4.95 (d, J=14.0, 1H), 4.91 (d, J=14.0,  1H), 4.79 (d, J=14.0,  1H). HRESIMS calcd for 
C19H18N7O3 m/z [M+H]
+
 392.1466, found 392.1469. 
1-{[2-(2,4-difluorophenyl)-2H,3H-imidazo[2,1-b][1,3]oxazol-2-yl]methyl}-1H-1,2,4-triazole 
(20): White powder (29 %): mp 134-137 
o
C (dec); 
1
H NMR [500 MHz, (CD3)2CO] δ: 8.35 (s, 
1H), 7.72 (s, 1H), 7.49 (ddd, J=17.5, 9.0, 6.5 Hz, 1H), 7.21 (ddd, J=11.5, 9.0, 2.5 Hz, 1H), 7.05 (dddd, 
J=11.5, 9.0, 3.0, 1.0 Hz, 1H), 6.66 (d, J=1.5 Hz, 1H), 6.51 (d, J=1.5 Hz, 1H), 5.04 (d, J=15.0 Hz, 1H), 
4.95 (d, J=15.0 Hz, 1H), 4.88 (dd, J=11.0, 2.0 Hz, 1H), 4.46 (dd, J=11.0, 2.0 Hz, 1H). HRESIMS calcd 
for C14H12F2N5O and C14H11F2N5NaO m/z [M+H]
+
 and [M+Na]
+
 304.1004 and 326.0824, found 304.1006 
and 326.0829. 
4-Methyl-N-[1-(3-nitro-1H-1,2,4-triazol-1-yl)-3-phenylpropan-2-yl]benzene-1-sulfonamide 
(21): 3-Nitro-1,2,4-triazole (0.68 mmol) was dissolved in dry 1-propanol (5 mL) and then NaH 
(60%, 1.05 eq)  was added. Then the commercially available (Aldrich) S-(+)-2-benzyl-1-(p-
tosylaziridine) (0.68 mmol) was added and the reaction mixture was refluxed for 6 h. The 
reaction mixture was chromatographed on silica gel plates with ethyl acetate-petroleum ether 
(60:40) as eluent. White crystals (36 %): mp 147-148 
o
C; 
1
H NMR (400 MHz, CDCl3) δ: 8.18 (s, 
1H), 7.43 (d, J=8.0 Hz, 2H), 7.26 (m, 3H), 7.18 (d, J=8.0 Hz, 2H), 7.00 (m, 2H), 4.64 (d, J=7.2 Hz, 1H), 
4.54 (dd, J=14.0, 4.0 Hz, 1H), 4.20 (dd, J=14.8, 6.8 Hz, 1H), 3.83 (m, 1H), 2.96 (dd, J=14.8, 6.8 Hz, 1H), 
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2.75 (dd, J=14.4, 7.2 Hz, 1H), 2.42 (s, 3H). HRESIMS calcd for C18H20N5O4S m/z [M+H]
+
 402.1231, 
found 402.1235. 
1-(4-(2-methyloxiran-2-yl)phenyl)-1H-imidazole (22): This compound was isolated during 
the synthesis of compound 14. White crystals (17%): mp 79-81 
o
C; 
1
H NMR [500 MHz, 
(CD3)2CO] δ: 8.05 (s, 1H), 7.58 (d, J=8.5 Hz, 2H), 7.56 (s, 1H), 7.53 (d, J=8.5 Hz, 2H), 3.00 (d, J=5.5 
Hz, 1H), 2.77 (d, J=5.5 Hz, 1H), 1.71 (s, 3H). HRESIMS calcd for C12H13N2O m/z [M+H]
+
 201.1022, 
found 201.1024. 
Biological evaluation. In vitro screening: In vitro activity against T. cruzi, T. b. rhodesiense, 
and cytotoxicity assessment using L6 cells (rat skeletal myoblasts) was determined using a 96-
well plate format as previously described.
31
 Data were analyzed with the graphic program 
Softmax Pro (Molecular Devices, Sunnyvale, CA, USA), which calculated IC50 values by linear 
regression from the sigmoidal dose inhibition curves. 
Enzymatic activity studies with Type I NTR. Recombinant TbNTR was prepared and assayed 
as previously described.
33,34
 The activity of purified his-tagged TbNTR was assessed 
spectrophotometrically at 340 nm using various nitrotriazole substrates (100 µM) and NADH 
(100 µM) and expressed as nmol NADH oxidized min
-1
 mg
-1
 of enzyme.  
Testing T. cruzi CYP51 as a potential inhibition target. Selected compounds (2, 18 and 19) 
were evaluated as CYP51 ligand/inhibitors using purified full-length T. cruzi CYP51 protein 
sample.
28
 Binding affinities of the compounds were estimated using spectral titration. The 
experiments were performed on a dualbeam Shimadzu UV-240IPC spectrophotometer in the 
wavelength range 350−450 nm at 25 °C in 2 mL tandem cuvettes at 2 μM P450 and ligand 
concentrations ranging from 0.5 to 10 μM. The apparent dissociation constants were calculated 
by plotting the absorbance changes in the difference spectra (ΔA425−390) upon titration against 
21 
 
free ligand concentration and fitting the data to a rectangular hyperbola in Sigma Plot Statistics. 
Inhibitory potencies of the compounds were compared in the reconstituted CYP51 reaction 5 min 
and 1 h, at 50/2/1 molar ratio substrate/inhibitor/enzyme. P450 concentration in the reaction 
mixture was 1 μM. The reaction products were analyzed on a reverse-phase HPLC system 
(Waters) equipped with a C18Nova Pak column and a β-RAM detector (INUS Systems, Inc.).9 
In vivo antichagasic activity assessment of selected compounds. For in vivo studies, a 
Brazilian strain trypomastigotes from transgenic T. cruzi parasites expressing firefly luciferase 
were used as described before.
19
 Briefly, parasites were injected in Balb/c mice (10
5
 
trypomastigotes per mouse) and three days later mice were anesthesized by inhalation of 
isofluorane, followed by an injection with 150 mg/kg of D-luciferin potassium-salt in PBS. Mice 
were imaged 5 to 10 min after injection of luciferin with an IVIS 100 (Xenogen, Alameda, CA) 
and the data acquisition and analysis were performed with the software LivingImage (Xenogen) 
as described before.
35
 Treatment with test compounds was started 4 days after infection at a 
specific concentration (usually 15 mg/kg/day x 10 days) by i.p. injection.  The vehicle control 
was 2% methylcellulose + 0.5% Tween 80  and groups of 5 mice/group were used. In the vehicle 
control group 10 mice were used. Mice were imaged on days 5 and 10 as above. Parasite index 
was calculated as the ratio of parasite levels in treated mice compared to the control group and 
multiplied by 100. The ratio of parasite levels is calculated for each animal dividing the 
luciferase signal after treatment by the luciferase signal on the first imaging (before treatment). 
Mean values of all animals in each group  SD were then used to calculate the parasite index.35 
In vitro ADME studies. ADME in vitro studies were performed by APREDICA (Watertown, 
MA). Samples were analyzed by LC/MS/MS using an Agilent 6410 mass spectrometer coupled 
with an Agilent 1200 HPLC and a CTC PAL chilled autosampler, all controlled by MassHunter 
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software (Agilent). After separation on a C18 reverse phase HPLC column (Agilent, Waters, or 
equivalent) using an acetonitrile-water gradient system, peaks were analyzed by mass 
spectrometry (MS) using ESI ionization in MRM mode. 
Microsomal stability screen: Each test compound was dissolved in DMSO and incubated (37 
ºC) at 1 μM final concentration with 0.3 mg/mL of microsomal protein in 100 mM potassium 
phosphate, 3 mM MgCl2, pH 7.4, in the presence or absence of 2 mM NADPH (to detect 
NADPH-free degradation) for up to 60 min as has been described before.
19
 Data were reported as 
% remaining parent compound. 
 Caco-2 monolayer permeability studies: Caco-2 cells grown in tissue culture flasks were 
trypsinized, suspended in medium, and the suspensions were applied to wells of a collagen-
coated BioCoat Cell Environment in 96-well format. The cells were allowed to grow and 
differentiate for three weeks, feeding at 2-day intervals. For Apical to Basolateral (A→B) 
permeability, the test agent was added to the apical (A) side at 10 μM final concentration and 
amount of permeation was determined on the basolateral (B) side after 2 h assay time as 
described before.
19
 Data were expressed as permeability (Papp):  Papp = (dQ/dt)/C0A, where 
dQ/dt is the rate of permeation, C0 is the initial concentration of test agent, and A is the area of 
the monolayer.
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 ABBREVIATIONS USED 
NTD, Neglected tropical diseases; T. cruzi, Trypanosoma cruzi; T. brucei, Trypanosoma brucei; 
HAT, human African trypanosomiasis; Nfx, nifurtimox (4-(5-nitrofurfurylindenamino)-3-
methylthio-morpholine-1,1-dioxide); Bnz, benznidazole (N-benzyl-2-(2-nitro-1H-imidazol-1-
yl)acetamide); NTR, type I nitroreductase; TcNTR, T. cruzi NTR; TbNTR, T. brucei NTR; 
CYP51, sterol 14-demethylase enzyme; TcCYP51, T. cruzi CYP51; IC50, concentration for 
50% growth inhibition; SI, selectivity index; SARs, structure-activity relationships; TDR, 
Tropical Diseases Research (http://www.who.int/tdr/en/). 
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Table 1. In vitro antiparasitic activity, host toxicity and physical properties of tested compounds. 
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Table 1. (continuation) 
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a
T.b. rhodesiense, strain STIB 900 trypomastigotes; 
b
 T. cruzi, strain Tulahuen C4 amastigotes; 
SI is the ratio: IC50 in L6 cells/IC50 in each parasite. 
c
Cytotoxicity in host L6 cells. Reference 
drugs: Melarsoprol (Melars) and Benznidazole (Bnz). The IC50 value of each reference drug is 
the mean from multiple measurements in parallel with the compounds of interest. Active and 
moderately active compounds with acceptable selectivity are colored green and pink, 
respectively; compounds with an unacceptable selectivity are colored blue whereas inactive 
compounds are colorless. PSA: polar surface area. All physical properties were predicted by 
using the Marvin Calculator (www.chemaxon.com). Values are means of 2 to 3 measurements. 
The SD was < 5%. Data for compound 23 are taken from ref. [17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
Scheme 1. Preparation of compounds 2-21 
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Table 2. Enzymatic activity of recombinant TbNTR and TcNTR toward 
Bnz and representative 3-nitrotriazoles from Table 1.  
compound 
Specific activity values 
(nmol NADH oxidized per min per mg 
NTR) 
 
TbNTR TcNTR 
Bnz 1540 ± 67 680 ± 8 
2 3172 ± 11 888 ± 24 
14 3456 ± 6 1067 ± 16 
18 3063 ± 43 1178 ± 10 
19 2681 ± 21 1160 ± 19 
A precipitation issue occurred with compound 2 in the assay  
buffer used. Enzyme assays were carried out in triplicate and  
repeated twice. 
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Table 3. Binding of compounds to recombinant T. cruzi CYP51 
 
Kd: Dissociation constant. I/E2: Molar ratio of inhibitor/enzyme 
which causes a 2-fold decrease in enzyme activity in 5 min and 1 
hour reactions. ND: Not determined. *Values for Bnz were taken 
from Ref. [30]. 
 
 
 
 
 
 
 
 
 
 
 
Compound Kd (μM) I/E2 (5 min) I/E2 (1 h)
2 ND 4 36
18 0.606 ± 0.023 5 32
19 0.023 ± 0.012 <1 3
23 65.2 ± 5.3 ND ND
Fluconazole 0.230 0.029 <1 16
Bnz* ND 43.2 45
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Table 4. In vitro ADME data for compounds 2 and 19. 
 
Papp: Caco 2 apparent permeability. Permeability ranking: Low: <0.5; Moderate:  
0.5 - 5; High: > 5. For permeability measurements 10 μM concentration was used  
and 2 h assay time. For metabolic stability, 1 μM concentration and 0 and 60 min 
incubation time was used. Test species represent either human or mouse microsomes. 
 
 
 
 
 
 
 
 
Compound
mean A->B
Papp                
(x10-6cm s-1)
Test species
Mean remaining 
parent, with 
NADPH (%)
Mean remaining 
parent, free of 
NADPH (%)
2 18.7
Human    
Mouse
96.8                 
79.4
84.8                    
110
19 16.5
Human    
Mouse
90.7                 
77.6
106                     
102
Verapamile
Human    
Mouse
8.4                      
6.0
89.4                   
96.5
Warfarin 25.3
Human    
Mouse
102                    
104
96.7                    
101
Ranitidine 0.24
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Fig. 1. Binding of fluconazole and compound 18 (NO2-fluconazole) to T. cruzi CYP51. Both 
compounds produce typical type 2 spectral response in T. cruzi CYP51, indicating at least initial 
coordination of triazole N4 to the P450 heme iron. However, compound 18 is a weaker binder. 
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Fig. 2. Binding (left panel) and inhibition (right panel) of T. cruzi CYP51 by compound 19 in 5 
min and 1 h reactions. The same results were obtained independently of the sequence that 
substrate eburicol (S) or inhibitor (I) were added, namely: Reaction mixture + I/+NADPH, 5 min 
incubation at 37
o
C /+S or, Reaction mixture + I +S /+NADPH. 
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Fig. 3. In vivo evaluation of the antichagasic efficacy of compounds 2, 5, 18 and 19 in the acute 
murine model. Benznidazole (Bnz) data from 2 experiments in parallel were included. All 
compounds except 5 were administered (i.p.) at 15 mg/kg/day. Compound 5 was administered 
(i.p.) at 13 mg/kg/day.  The P values refer to comparisons between treated groups and control 
group. When P values are not given, there was no statistical difference. Groups of 5 mice/group 
were used. Occasionally, 10 mice were used in the control group. 
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Fig. 4. Images from mice treated with vehicle or compounds 5 and 19. 
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